In oncology, particularly in breast cancer (mammary carcinoma), long-read sequencing can enhance the detection of variants in genes such as BRCA1, BRCA2, TP53, PIK3CA, and CHEK2, which are critical for risk stratification, therapeutic targeting, and treatment response monitoring. Here, TP53 is linked to breast carcinoma.